Program
saruparib
Also written as “Saruparib”, “Saruparib (AZD5305)” and “AZD5305”.
Its studies are mostly in Prostatic Neoplasms · Ovarian Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Neoplasms, led by AstraZeneca.
Drug pageAZD5305: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1411 open or running | phase 3since Oct 17, 2023 | Jul 30, 2014 | Dec 31, 2026phase 1 · NCT06713369 |
- Named in AstraZeneca’s own pipeline as
saruparib
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: Fortrea, Parexel and Bayer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 30, 2014.
- Oct 26, 2020Phase 2 study in Ovarian NeoplasmsNCT04644068 · 702 enrolled · United States, Australia, Canada and more
- Oct 13, 2021Phase 2 study in Breast NeoplasmsNCT05123482 · 460 planned · United States, Australia, Belgium and more
- Apr 19, 2022Phase 2 study in Prostatic NeoplasmsNCT05367440 · 174 enrolled · United States, Australia, Italy and more
- Oct 7, 2022Phase 1 study in NeoplasmsNCT05573724 · 16 enrolled · Moldova, Republic of, Romania
- Jan 19, 2023Named saruparibINNProposed as its International Nonproprietary Name in WHO's List 128 · before, AZD5305
- May 16, 2023Phase 1 study in Prostatic NeoplasmsNCT05938270 · 113 enrolled · United States, Australia, Canada and more
- Oct 17, 2023Phase 3 study in Prostatic NeoplasmsNCT06120491 · 1,898 enrolled · United States, Australia, Austria and more
- Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
- Jul 30, 2024Phase 1 study in Neoplasm MetastasisNCT06713369 · 8 planned · United Kingdom
- Mar 21, 2025Phase 1 study in Advanced Solid MalignanciesNCT06899061 · 41 enrolled · Bulgaria, Moldova, Romania
- Apr 30, 2025Phase 3 study in Prostatic NeoplasmsNCT06952803 · 700 planned · United States, Argentina, Australia and more
- Jun 24, 2025Phase 2 study in Ovarian NeoplasmsNCT07060365 · Spain
- Feb 26, 2026Phase 2 study in Solid TumoursNCT07446855 · 180 planned · United States, Australia, Japan and more
- Jul 14, 2026Phase 3 study in Prostatic NeoplasmsNCT07711002 · 1,330 planned · United States, Austria, Brazil and more
- Nov 12, 2026Primary completion moved from 2026-10-02 to 2026-12-31Date moved laterphase 1 · +3 months · NCT06713369
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT06713369
- May 28, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT04644068
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
- Sep 30, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06120491
TargetBeta
“An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, saruparib selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks vi…”NCIt, read by Claude
“Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.”study text, by rule · the study
Other programs on the same two targets
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07711002Prostatic Neoplasms · United States, Austria, Brazil and more | 3 | Recruiting | May 30, 2031 | 1,330 |
| NCT07446855Solid Tumours · United States, Australia, Japan and more | 2 | Recruiting | Mar 29, 2030 | 180 |
| NCT07060365Ovarian Neoplasms · Spain | 2 | Withdrawn | Dec 19, 2025 | 0 |
| NCT06952803Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 31, 2033 | 700 |
| NCT06899061Advanced Solid Malignancies · Bulgaria, Moldova, Romania | 1 | Active, not recruiting | Feb 3, 2026 | 41 |
| NCT06713369Neoplasm Metastasis · United Kingdom | 1 | Recruiting | Dec 31, 2026 | 8 |
| NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 788 |
| NCT06120491Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Sep 30, 2027 | 1,898 |
| NCT05938270Prostatic Neoplasms · United States, Australia, Canada and more | 1 | Completed | Jun 15, 2026 | 113 |
| NCT05573724Neoplasms · Moldova, Republic of, Romania | 1 | Completed | Apr 17, 2023 | 16 |
| NCT05367440Prostatic Neoplasms · United States, Australia, Italy and more | 2 | Active, not recruiting | Apr 11, 2031 | 174 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 29, 2027 | 460 |
| NCT04644068Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | May 28, 2027 | 702 |
| NCT02264678Ovarian Neoplasms · United States, France, South Korea and more | 1 | Active, not recruiting | Mar 4, 2025 | 358 |
How it is read
Names in the registry
- “Saruparib”, 6 entries
- “Saruparib (AZD5305)”, 3 entries
- “AZD5305”, 3 entries
- “[14C]-AZD5305 microtracer”, 1 entry
- “[14C]-AZD5305 (therapeutic dose)”, 1 entry
Codes read as this program: AZD5305.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 5 studies
- Ovarian Neoplasms, 3 studies
- Breast Neoplasms, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.